High-avidity antitumor T-cell generation by toll receptor 8–primed, myeloid- derived dendritic cells is mediated by IL-12 production

High-level production of heterodimeric p70 interleukin (IL)-12 by myeloid-derived dendritic cells (DCs) requires 2 signals: interferon gamma (IFN-γ) and a maturation signal provided by CD40 ligation (CD40L) or lipopolysaccharide (LPS). In the current study we demonstrate that signaling through toll-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgery 2006-08, Vol.140 (2), p.170-178
Hauptverfasser: Xu, Shuwen, Koldovsky, Ursula, Xu, Min, Wang, Daniel, Fitzpatrick, Elizabeth, Son, Gilsoo, Koski, Gary, Czerniecki, Brian J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:High-level production of heterodimeric p70 interleukin (IL)-12 by myeloid-derived dendritic cells (DCs) requires 2 signals: interferon gamma (IFN-γ) and a maturation signal provided by CD40 ligation (CD40L) or lipopolysaccharide (LPS). In the current study we demonstrate that signaling through toll-like receptor (TLR) 8, but not TLR3, TLR2, or TLR4, provides a priming signal to myeloid-derived DC for high IL-12 p70 heterodimer production. All the TLR agonists induced maturation of DC as evidenced by increased expression of CD83, CD80, and CD86. Both IFN-γ and TLR7/8 agonist R848 increased expression of TLR8 in immature monocyte-derived DCs. The combination of TLR7/8 agonist R848 and maturation signals LPS or CD40L induced high-level expression of IL-12p35 and p40 similar to that induced by IFN-γ plus LPS. In contrast, receptor agonists specific for TLR7 did not prime for IL-12 production. The p70 IL-12 produced by the TLR8-primed DC polarized CD4+ T for Th1 cytokine production and induced CD8+ T cells, displaying high functional avidity with enhanced tumor cell recognition. The data suggest that toll 8 receptor agonists are useful for inducing type-1 polarized DCs for vaccine design in treating cancer and infectious disease.
ISSN:0039-6060
1532-7361
DOI:10.1016/j.surg.2006.03.006